AN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMPRENAVIR (141W94) AND ABACAVIR COMBINATION THERAPY IN PROTEASE INHIBITOR EXPERIENCED SUBJECTS WITH HIV-1 INFECTION WHO ARE FAILING THEIR CURRENT ANTIRETROVIRAL TREATMENT REGIMEN: